Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2004

View Archived Issues

Topical NO donor DS1 increases vaginal blood flow in rats

Rockwell receives grant for proprietary dialysate iron therapy study

Positive Life-Star and Health-Star phase III results due shortly

Fujisawa enters option agreement for distribution of Ampligen

Inflammation and elevated C-reactive protein increase the risk of colon cancer

Oral rhIL-11 improves mucosal inflammation in chronic colitis model

NO plays an important role in improving insulin action by pioglitazone

Karo Bio highlights developments over past year

Immunomedics reports continued growth of product pipeline during Q2 FY 2004

New macrolide-containing conjugates and their use reported by Pliva

Two series of macrolide-containing antiinflammatory agents developed at Pliva

Researchers at Karo Bio and BMS present novel thyroid receptor modulators

New mitotic kinesin KSP inhibitors jointly reported by Cytokinetics and GSK

Novel antibacterial cephalosporins covered by Sandoz patent

Novel antiproliferative agents in early development at Bayer

AstraZeneca scientists identify novel CRTh2 receptor modulators

Cytopia and Myomatrix enter cardiovascular collaboration

U. Pittsburgh Medical Center acquires RheoGene

BioMarin initiates PKU clinical program

Schwarz Pharma obtains rights to PAC-20030

Research at CSIRO shows Relenza effective against bird flu in laboratory

Thalomid sNDA accepted for review

Generex collaboration to develop DNA vaccine against SARS

Enrollment extended in AIM study of I2S in Hunter syndrome

NIH studies GPI-1485 in phase II Parkinson's trial

Nabi reports preliminary results from phase I/II Cicavir study

Oral phenoxodiol evaluated in phase I trial for cervical cancer

Vidaza NDA accepted for filing

NDA submission for six-month Eligard product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.